These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

461 related articles for article (PubMed ID: 31275298)

  • 1. Dipeptidyl Peptidase-4 Inhibitor-Associated Bullous Pemphigoid.
    Tasanen K; Varpuluoma O; Nishie W
    Front Immunol; 2019; 10():1238. PubMed ID: 31275298
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Dipeptidyl peptidase IV inhibitor-associated bullous pemphigoid: a recently recognized autoimmune blistering disease with unique clinical, immunological and genetic characteristics.
    Nishie W
    Immunol Med; 2019 Mar; 42(1):22-28. PubMed ID: 31169082
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Gliptin-associated Bullous Pemphigoid and the Expression of Dipeptidyl Peptidase-4/CD26 in Bullous Pemphigoid.
    Lindgren O; Varpuluoma O; Tuusa J; Ilonen J; Huilaja L; Kokkonen N; Tasanen K
    Acta Derm Venereol; 2019 May; 99(6):602-609. PubMed ID: 30848289
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Preferential Reactivity of Dipeptidyl Peptidase-IV Inhibitor-Associated Bullous Pemphigoid Autoantibodies to the Processed Extracellular Domains of BP180.
    Mai Y; Nishie W; Izumi K; Shimizu H
    Front Immunol; 2019; 10():1224. PubMed ID: 31191560
    [TBL] [Abstract][Full Text] [Related]  

  • 5. A Cross-Sectional Study Comparing the Prevalence of Bullous Pemphigoid Autoantibodies in 275 Cases of Type II Diabetes Mellitus Treated With or Without Dipeptidyl Peptidase-IV Inhibitors.
    Izumi K; Nishie W; Beniko M; Shimizu H
    Front Immunol; 2019; 10():1439. PubMed ID: 31297116
    [No Abstract]   [Full Text] [Related]  

  • 6. Use of gliptins reduces levels of SDF-1/CXCL12 in bullous pemphigoid and type 2 diabetes, but does not increase autoantibodies against BP180 in diabetic patients.
    Nätynki A; Leisti P; Tuusa J; Varpuluoma O; Huilaja L; Izumi K; Herukka SK; Ukkola O; Junttila J; Kokkonen N; Tasanen K
    Front Immunol; 2022; 13():942131. PubMed ID: 35958564
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Gliptin Accountability in Mucous Membrane Pemphigoid Induction in 24 Out of 313 Patients.
    Gaudin O; Seta V; Alexandre M; Bohelay G; Aucouturier F; Mignot-Grootenboer S; Ingen-Housz-Oro S; Bernardeschi C; Schneider P; Mellottee B; Caux F; Prost-Squarcioni C
    Front Immunol; 2018; 9():1030. PubMed ID: 29881377
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Bullous pemphigoid induced by dipeptidyl peptidase-4 inhibitors. Eight cases with clinical and immunological characterization.
    García-Díez I; Ivars-Lleó M; López-Aventín D; Ishii N; Hashimoto T; Iranzo P; Pujol RM; España A; Herrero-Gonzalez JE
    Int J Dermatol; 2018 Jul; 57(7):810-816. PubMed ID: 29682739
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Dipeptidyl peptidase-4 inhibitor-associated bullous pemphigoid, likely triggered by scabies, in a hemodialysis patient with human leukocyte antigen-DQB1*03:01.
    Hibi A; Kasahara Y; Ishihara Y; Hata K; Hosokawa N; Nakagawa T
    CEN Case Rep; 2020 Aug; 9(3):189-194. PubMed ID: 31993957
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Decrease in eosinophils infiltrating into the skin of patients with dipeptidyl peptidase-4 inhibitor-related bullous pemphigoid.
    Chijiwa C; Takeoka S; Kamata M; Tateishi M; Fukaya S; Hayashi K; Fukuyasu A; Tanaka T; Ishikawa T; Ohnishi T; Watanabe S; Tada Y
    J Dermatol; 2018 May; 45(5):596-599. PubMed ID: 29411416
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Clinical and immunological profile of patients with dipeptidyl peptidase-4 inhibitor-associated bullous pemphigoid.
    Bellinato F; Maurelli M; Schena D; Gisondi P; Girolomoni G
    Ital J Dermatol Venerol; 2021 Aug; 156(4):455-459. PubMed ID: 32545941
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Bullous pemphigoid in diabetic patients treated by gliptins: the other side of the coin.
    Chouchane K; Di Zenzo G; Pitocco D; Calabrese L; De Simone C
    J Transl Med; 2021 Dec; 19(1):520. PubMed ID: 34930319
    [TBL] [Abstract][Full Text] [Related]  

  • 13. More Severe Erosive Phenotype Despite Lower Circulating Autoantibody Levels in Dipeptidyl Peptidase-4 Inhibitor (DPP4i)-Associated Bullous Pemphigoid: A Retrospective Cohort Study.
    Ständer S; Schmidt E; Zillikens D; Ludwig RJ; Kridin K
    Am J Clin Dermatol; 2021 Jan; 22(1):117-127. PubMed ID: 33026629
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Clinical features of dipeptidyl peptidase-4 inhibitor-associated bullous pemphigoid in Japan: A nationwide retrospective observational study.
    Sugiyama S; Yamamoto T; Aoyama Y
    J Dermatol; 2022 Jul; 49(7):697-702. PubMed ID: 35478414
    [TBL] [Abstract][Full Text] [Related]  

  • 15. A case of anti-BP230 antibody-positive bullous pemphigoid receiving DPP-4 inhibitor.
    Sawada K; Sawada T; Kobayashi T; Fujiki A; Matsushita T; Kawara S; Izumi K; Nishie W; Shimizu H; Takehara K; Hamaguchi Y
    Immunol Med; 2021 Mar; 44(1):53-55. PubMed ID: 32634333
    [TBL] [Abstract][Full Text] [Related]  

  • 16. The association of bullous pemphigoid with dipeptidyl-peptidase 4 inhibitors: a ten-year prospective observational study.
    Lambadiari V; Kountouri A; Kousathana F; Korakas E; Kokkalis G; Theotokoglou S; Palaiodimou L; Katsimbri P; Ikonomidis I; Theodoropoulos K; Papadavid E
    BMC Endocr Disord; 2021 Feb; 21(1):23. PubMed ID: 33573656
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Association of Bullous Pemphigoid With Dipeptidyl-Peptidase 4 Inhibitors in Patients With Diabetes: Estimating the Risk of the New Agents and Characterizing the Patients.
    Kridin K; Bergman R
    JAMA Dermatol; 2018 Oct; 154(10):1152-1158. PubMed ID: 30090931
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Case Report: Appearance of Various Disease-Specific Antibodies After the Onset of Dipeptidyl Peptidase-4 Inhibitor-Associated Bullous Pemphigoid.
    Iwamoto Y; Anno T; Koyama K; Kawasaki F; Kaku K; Tomoda K; Sugiyama S; Aoyama Y; Kaneto H
    Front Immunol; 2022; 13():843480. PubMed ID: 35309321
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Analysis of the Clinical Characteristics of Dipeptidyl Peptidase-4 Inhibitor-Induced Bullous Pemphigoid.
    Sun L; Wang C; Wu C; Zhou Y; Wang C
    Ann Pharmacother; 2022 Feb; 56(2):205-212. PubMed ID: 34105395
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Gliptin-associated bullous pemphigoid shows peculiar features of anti-BP180 and -BP230 humoral response: Results of a multicenter study.
    Salemme A; Fania L; Scarabello A; Caproni M; Marzano AV; Cozzani E; Feliciani C; De Simone C; Papini M; Satta RR; Parodi A; Mariotti F; Lechiancole S; Genovese G; Passarelli F; Festa F; Bellei B; Provini A; Sordi D; Pallotta S; Abeni D; Mazzanti C; Didona B; Di Zenzo G;
    J Am Acad Dermatol; 2022 Jul; 87(1):56-63. PubMed ID: 35240229
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 24.